Literature DB >> 9859920

Animal models for Chlamydia pneumoniae infection.

P Saikku1, K Laitinen, M Leinonen.   

Abstract

Animal models are used extensively in the ongoing investigation of a possible causal link between Chlamydia pneumoniae infection and conditions such as asthma and cardiovascular disease. Respiratory infections have been studied in monkeys, while mouse and rabbit models have been used to study both respiratory and cardiovascular infections. The degree of disease induced in mice depends on the strain used, the virulence of the C. pneumoniae strain used, and the dose administered. A characteristic mononuclear pneumonitis occurs, although the infection is systemic and the agent is found outside the lungs, in the circulation, spleen and liver. The infective dose used in the model tends to produce persistent infection, with inflammation continuing after the agent can no longer be cultured from the lungs. In reinfected animals the titre of infective chlamydia in lungs is much diminished, but the inflammation can be quite marked. The continuous persistence of the agent can be demonstrated by polymerase chain reaction (PCR), or, in chronically infected animals, after immunosuppression with cortisone. New Zealand White (NZW) rabbits provide an experimental model, not only for lung infections, but also for C. pneumoniae-induced atherosclerosis. Three laboratories have now reported that after inoculation, plaques develop in the arterial walls of experimental animals on a normal diet. In addition, one laboratory has reported from their studies on atherosclerosis in apoE-deficient and normal mice, that the persistence of the agent in aortic walls could be seen. Further studies are needed to evaluate the effect of the strain of chlamydia and dosage used, the importance of reinfection, the effect of diet and the effect of antibiotic treatment in these models.

Entities:  

Mesh:

Year:  1998        PMID: 9859920     DOI: 10.1016/s0021-9150(98)00115-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Chlamydophila pneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung diseases.

Authors:  N Teig; A Anders; C Schmidt; C Rieger; S Gatermann
Journal:  Thorax       Date:  2005-09-02       Impact factor: 9.139

2.  Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.

Authors:  Weidang Li; Pareesha Gudipaty; Chuxi Li; Kyle K Henderson; Kyle H Ramsey; Ashlesh K Murthy
Journal:  Immunol Cell Biol       Date:  2018-08-23       Impact factor: 5.126

3.  Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events.

Authors:  J B Muhlestein
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

Review 4.  Immunopathogenesis of Chlamydial Infections.

Authors:  Ashlesh K Murthy; Weidang Li; Kyle H Ramsey
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

5.  Proteus mirabilis Targets Atherosclerosis Plaques in Human Coronary Arteries via DC-SIGN (CD209).

Authors:  Ying Xue; Qiao Li; Chae Gyu Park; John D Klena; Andrey P Anisimov; Ziyong Sun; Xiang Wei; Tie Chen
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.